Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Retlirafusp alfa by Jiangsu Hengrui Medicine for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Squamous Non-Small Cell Lung...
Retlirafusp alfa by Jiangsu Hengrui Medicine for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma)....
Retlirafusp alfa by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma: Likelihood of Approval
Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Hepatocellular Carcinoma. According to...
Retlirafusp alfa by Jiangsu Hengrui Medicine for Melanoma: Likelihood of Approval
Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Melanoma. According to GlobalData,...
Retlirafusp alfa by Jiangsu Hengrui Medicine for Recurrent Head And Neck Squamous Cell Carcinoma: Likelihood of Approval
Retlirafusp alfa is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Recurrent Head And Neck...